New Anticancer Drug Manipulating the Body’s Natural Signaling and Energy System Dramatically Improves Cancer Survival
Published on 25th March
A revolutionary breakthrough in the treatment of cancer could soon be underway following an important discovery which may lead to a dramatic improvement in cancer survival rates.
A new study published today in the International edition of Angewandte Chemie, reports how researchers at theUniversity of Warwickhave developed a new drug that can manipulate the body’s natural signaling and energy systems, allowing the body to attack and shut down cancerous cells.
Replacing Currently used Cancer Drugs
The new drug, called ZL105, is a compound based on the precious metal iridium. The study has found ZL105 could potentially replace currently used anticancer drugs, which become less effective over time, cause a wide-range of side-effects and damage healthy cells as well as cancerous.
New iridium-based drug is specifically designed not to attack DNA, but to have a novel mechanism of action, meaning that it could not only dramatically slow down and halt cancer growth, but also significantly reduce the side effects…
Commenting on the breakthrough, University of Warwick researcher and study co-author Isolda Romero-Canelon noted “The energy-producing machinery in cancer cells works to the limit as it attempts to keep up with quick proliferation and invasion. This makes cancer cells susceptible to minor changes in the cell ‘power-house’. Our drug pushes cancer cells over the limit causing them to slow and shut down, whilst normal cells can cope with its effects”.
Preliminary data indicate that the novel drug may be ten times more effective in treating ovarian, colon, melanoma, renal, and some breast cancers, according to data obtained by the US National Cancer Institute. The researchers now aim to expand the study to cancers that are inherently resistant to existing drugs and to those which have developed resistance after a first round of chemotherapy treatments.
“Existing cancer treatments often become less effective after the first course, as cancer cells learn how they are being attacked. The drug we have developed is a catalyst and is active at low doses. It can attack cancer cells in multiple ways at the same time, so the cancer is less able to adapt to the treatment. This means the new drugs could be much more effective than existing treatments,” noted the study’s co-author Professor Peter J. Sadler.
“Platinum-based drugs are used in nearly 50% of all chemotherapeutic regimens, exert their activity by damaging DNA and cannot select between cancerous and non-cancerous cells, leading to a wide-range of side-effects from renal failure to neurotoxicity, ototoxicity, nausea and vomiting.”
“In contrast, the new iridium-based drug is specifically designed not to attack DNA, but to have a novel mechanism of action, meaning that it could not only dramatically slow down and halt cancer growth, but also significantly reduce the side effects suffered by patients” Sadler argued.
This research could also lead to substantial improvements in cancer survival rates. “Current statistics indicate that one in every three people will develop some kind of cancer during their life time, moreover approximately one woman dies of ovarian cancer every two hours in the UK according to Cancer Research UK .It is clear that a new generation of drugs is necessary to save more lives and our research points to a highly effective way of defeating cancerous cells” Romero-Canelon noted.
For more information:
The Potent Oxidant Anticancer Activity of Organoiridium Catalysts.Liu Z, Romero-Canelón I, Qamar B, Hearn JM, Habtemariam A, Barry NP, Pizarro AM, Clarkson GJ, Sadler PJ. The Potent Oxidant Anticancer Activity of Organoiridium Catalysts. Angew Chem Int Ed Engl. 2014 Mar 11. doi: 10.1002/anie.201311161.[Article][PubMed]
Photo: Professor Peter Sadler, University of Warwick. Photo Courtesy: University of Warwick.
Copyright © 2014 InPress Media Group/Sunvalley Communication. All rights reserved. Republication or redistribution of InPress Media Group/Sunvalley Communication content, including by framing or similar means, is expressly prohibited without the prior written consent of InPress Media Group/Sunvalley Communication. InPress Media Group/Sunvalley Communication shall not be liable for any errors or delays in the content, or for any actions taken in reliance thereon. Onco’Zine and Oncozine are registered trademarks and trademarks of Sunvalley Communication around the world.